PROK
Prokidney Corp.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Prokidney Corp.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Largest filed tie
0
filed ties
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
No thesis.
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 18 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Prokidney Corp.
1.07
pre 1.07 −4.46%
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Prokidney Corp..
Same SIC code · 6
Same SEC industry code: Amgen Inc, Gilead Sciences, Inc., Biogen Inc. and 3 more; no measured co-movers for Prokidney Corp..
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $25.2M | 25.33% | 0.00% |
| Morgan Stanley | $20.1M | 20.22% | +10.03% |
| BlackRockindex-like | $10.6M | 10.67% | +274.68% |
| Geodeindex-like | $4.9M | 4.91% | +94.26% |
| Bleichroeder | $4.1M | 4.10% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Suvretta | $25.2M | 25.33% | 0.00% |
| Morgan Stanley | $20.1M | 20.22% | +10.03% |
| BlackRockindex-like | $10.6M | 10.67% | +274.68% |
| Geodeindex-like | $4.9M | 4.91% | +94.26% |
| Bleichroeder | $4.1M | 4.10% | 0.00% |
Bull1
Bear2
Expected move
Inputsstraddle ±81.4%
spot 1.07exp Nov 20ATM strike 1ATM straddle 1.03IV 615%